DEXTROSTAT Trademark

Trademark Overview

On Tuesday, March 23, 2021, a trademark application was filed for DEXTROSTAT with the United States Patent and Trademark Office. The USPTO has given the DEXTROSTAT trademark a serial number of 90596136. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Thursday, July 4, 2024. This trademark is owned by Sunrise Pharmaceutical, Inc.. The DEXTROSTAT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for attention deficit disorder, hyperactivity and narcolepsy
dextrostat

General Information

Serial Number90596136
Word MarkDEXTROSTAT
Filing DateTuesday, March 23, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateThursday, July 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 30, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for attention deficit disorder, hyperactivity and narcolepsy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, June 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSunrise Pharmaceutical, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRahway, NJ 07065
Party NameSunrise Pharmaceutical, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRahway, NJ 07065

Trademark Events

Event DateEvent Description
Thursday, October 28, 2021ASSIGNED TO EXAMINER
Friday, March 26, 2021NEW APPLICATION ENTERED
Saturday, June 26, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 28, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 10, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 30, 2021PUBLISHED FOR OPPOSITION
Wednesday, June 29, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, November 30, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 25, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 5, 2023SOU EXTENSION 2 FILED
Wednesday, June 29, 2022SOU EXTENSION 1 FILED
Wednesday, June 29, 2022SOU EXTENSION 1 GRANTED
Friday, July 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 5, 2023SOU TEAS EXTENSION RECEIVED
Thursday, January 5, 2023SOU EXTENSION 2 GRANTED
Saturday, January 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 4, 2024SOU TEAS EXTENSION RECEIVED
Thursday, July 4, 2024SOU EXTENSION 5 GRANTED
Thursday, July 4, 2024SOU EXTENSION 5 FILED
Thursday, July 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 18, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 18, 2023SOU EXTENSION 3 FILED
Tuesday, July 18, 2023SOU EXTENSION 3 GRANTED
Thursday, July 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 17, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 17, 2024SOU EXTENSION 4 FILED
Wednesday, January 17, 2024SOU EXTENSION 4 GRANTED

Related Keywords

dextrostat hyperactivity narcolepsy disorder deficit preparations attention pharmaceutical